{# Audit 04/10/2026 : « autre » n'est pas un code de langue ; SPHAERO n'est pas l'éditeur des documents qu'elle héberge ou référence. #} {# citation_pdf_url doit mener à un PDF : un lien vers une page DOI est pénalisé par Google Scholar (avant : tout lien externe). #}
Accès ouvert · CC BY

Pregabalin for the treatment of generalized anxiety disorder

Article scientifique 2022 Anglais

Résumé

Introduction Pregabalin is a treatement with a complexe mechanism of action. It’s an antiepileptic drug used as adjunctive treatment of partial epilepsy, it is also taken in the treatment of neuropathic pain, and generalized anxiety disorder, in addition to epilepsy. Some of the advantages of pregabalin include. pharmacokinetics, safety, and tolerability. Clinical trials have demonstrated the efficacy of pregabalin comparable to benzodiazepines, without risk of abuse. Objectives to assess the efficacy of pregabalin in patients with generalized anxiety disorder in the Ar-Razi university psychiatric hospital in Salé in Morocco Methods To assess the place of pregabalin in the treatement of anxiety disorders through patients hospitalized in the Ar-Razi university psychiatric hospital in Salé in Morocco The evaluation instruments are: For anxiety the Hamilton Anxiety Scale and For therapeutic efficacy CGI-therapeutic index Results based on the results of our study on the patients who have improved after an optimal duration of treatment, in conjunction with psychological monitoring, we retain that pregabalin can significantly improve the quality of life of anxious patients and also guarantee them a better prognosis Conclusions Pregabalin was significantly more efficacious for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients. Disclosure No significant relationships.

Citer ce document

Khallouk, A., Rhaouti, A., Boukdir, A., Stati, S., Nafiaa, H., & Ouanass, A. (2022). Pregabalin for the treatment of generalized anxiety disorder. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.1011

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 06/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations : 1

Téléchargements : 0